Mind-body program for patients with blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial investigates the effectiveness of a mind-body group program designed to manage fatigue in patients with malignant hematological diseases who are in complete remission after primary treatment. Participants will engage in a series of group sessions focusing on mind-body techniques to enhance their overall well-being. The study aims to provide supportive therapy that complements traditional medical treatments for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with malignant hematological diseases in complete remission after primary chemotherapy and/or radiation
* Physical and mental ability to attent 8 of 11 group units

Exclusion Criteria:

* Chemotherapy, radiation, or rehabilitation programm during the study period
* Pregnancy
* Participation in other studies with behavioral interventions during the study period

Where it's running

• Robert-Bosch-Krankenhaus, Abteilung für Hämatologie, Onkologie und Palliativmedizin
  Stuttgart, Germany Recruiting

Study contacts

• Study coordinator: Holger Cramer, PhD
• Email: holger.cramer@med.uni-tuebingen.de
• Phone: +4971181017860

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Anti-CD25 antibody to prevent acute GVHD after haploidentical stem cell transplant

  This study tests whether an anti-CD25 antibody can better prevent acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation compared with the usual methotrexate-based approach.

  Recruiting Phase 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07689630

• KK2430 in people with hematologic cancers

  This study tests KK2430 in adults with blood-related cancers to see if it is safe and how it behaves in the body, with the goal of understanding its potential to help in treatment.

  Recruiting Phase 1/2 Kyowa Kirin Co., Ltd. · Greenville, South Carolina · NCT07629726

• JNJ-95804306 in relapsed or refractory blood cancers

  This study tests JNJ-95804306 in people with relapsed or refractory hematologic cancers to find a safe dose and see if it helps control the disease when given alone or with standard therapy.

  Recruiting at 19 sites Phase 1 Janssen Research & Development, LLC · Indianapolis, Indiana and 18 other locations · NCT07572006

• AI-written plain-language discharge summaries for people with blood and other cancers

  This project tests whether AI-written plain-language discharge letters help adults with hematologic or other cancers understand their diagnosis, treatment, and next steps better than the usual medical letter.

  Recruiting Technical University of Munich · Munich, Bavaria · NCT07519811

• Flu vaccine strategies for adults with blood cancers

  This study will test three different flu vaccines to see which gives the strongest antibody and T-cell responses in adults with blood cancers, including people after autologous stem cell transplant or CAR-T therapy.

  Recruiting Phase 3 Asan Medical Center · Seoul · NCT07485855

• Combining donor-derived anti-CD19 CAR-T cells with haploidentical transplant using post-transplant cyclophosphamide

  This trial tests whether giving donor-derived anti-CD19 CAR-T cells together with a haploidentical bone marrow transplant using post-transplant cyclophosphamide can help adults (18–75) with high‑risk CD19+ blood cancers.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07162038

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.